BELLA: A Phase 2 Study of Relacorilant + Nab-Paclitaxel +/- Bevacizumab in Patients with Gynecologic Cancers

Summary

There remains an unmet need for effective therapies in gynecologic cancers, including platinum-resistant and platinum-sensitive ovarian cancer, as well as endometrial cancer.
The BELLA phase 2 study is designed to evaluate the potential benefit of combining relacorilant + nab-paclitaxel with bevacizumab in ovarian cancer and relacorilant + nab-paclitaxel in endometrial cancer.
Findings from the BELLA study will expand our understanding of relacorilant-based combinations and inform future treatment strategies for patients with gynecologic cancers.

Scientific journal publications or scientific congress presentations may include information regarding investigational products or uses.